Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2000 4
2001 3
2002 5
2003 6
2004 14
2005 7
2006 15
2007 21
2008 26
2009 20
2010 27
2011 32
2012 39
2013 26
2014 17
2015 15
2016 19
2017 15
2018 10
2019 10
2020 13
2021 7
2022 7
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

313 results

Results by year

Filters applied: . Clear all
Page 1
Drospirenone/ethinyl estradiol.
Rapkin AJ, Sorger SN, Winer SA. Rapkin AJ, et al. Drugs Today (Barc). 2008 Feb;44(2):133-45. doi: 10.1358/dot.2008.44.2.1191057. Drugs Today (Barc). 2008. PMID: 18389090 Review.
Drospirenone 3 mg/ethinyl estradiol 20 microg (24/4) is a new unique oral contraceptive formulation that combines in a novel dosing regimen the lowest dosage of ethinyl estradiol commonly used today with drospirenone, an innovative progestin. Drospirenone is …
Drospirenone 3 mg/ethinyl estradiol 20 microg (24/4) is a new unique oral contraceptive formulation that combines in a novel dosing r …
Premenstrual disorders.
Yonkers KA, Simoni MK. Yonkers KA, et al. Am J Obstet Gynecol. 2018 Jan;218(1):68-74. doi: 10.1016/j.ajog.2017.05.045. Epub 2017 May 29. Am J Obstet Gynecol. 2018. PMID: 28571724 Review.
Combined oral contraceptives: venous thrombosis.
de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. de Bastos M, et al. Cochrane Database Syst Rev. 2014 Mar 3;2014(3):CD010813. doi: 10.1002/14651858.CD010813.pub2. Cochrane Database Syst Rev. 2014. PMID: 24590565 Free PMC article. Review.
The relative risk of venous thrombosis for combined oral contraceptives with 30-35 mug ethinylestradiol and gestodene, desogestrel, cyproterone acetate, or drospirenone were similar and about 50-80% higher than for combined oral contraceptives with levonorgestrel. ...Risk …
The relative risk of venous thrombosis for combined oral contraceptives with 30-35 mug ethinylestradiol and gestodene, desogestrel, cyproter …
Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results.
Creinin MD, Westhoff CL, Bouchard C, Chen MJ, Jensen JT, Kaunitz AM, Achilles SL, Foidart JM, Archer DF. Creinin MD, et al. Contraception. 2021 Sep;104(3):222-228. doi: 10.1016/j.contraception.2021.05.002. Epub 2021 May 15. Contraception. 2021. PMID: 34000251 Free article. Clinical Trial.
OBJECTIVE: To assess efficacy, cycle control, and safety of an oral contraceptive containing estetrol (E4) 15 mg and drospirenone (DRSP) 3 mg. STUDY DESIGN: Women aged 16 to 50 years with a body mass index 35 kg/m(2) enrolled in this multicenter, open-label, 13-cycle, phas …
OBJECTIVE: To assess efficacy, cycle control, and safety of an oral contraceptive containing estetrol (E4) 15 mg and drospirenone (DR …
A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception.
Dragoman MV, Tepper NK, Fu R, Curtis KM, Chou R, Gaffield ME. Dragoman MV, et al. Int J Gynaecol Obstet. 2018 Jun;141(3):287-294. doi: 10.1002/ijgo.12455. Epub 2018 Feb 22. Int J Gynaecol Obstet. 2018. PMID: 29388678 Free PMC article. Review.
The use of COCs containing cyproterone acetate, desogestrel, drospirenone, or gestodene was associated with a significantly increased risk of VTE compared with the use of levonorgestrel-containing COCs (pooled risk ratios 1.5-2.0). ...
The use of COCs containing cyproterone acetate, desogestrel, drospirenone, or gestodene was associated with a significantly increased …
Treatment of lean PCOS teenagers: a follow-up comparison between Myo-Inositol and oral contraceptives.
Pkhaladze L, Russo M, Unfer V, Nordio M, Basciani S, Khomasuridze A. Pkhaladze L, et al. Eur Rev Med Pharmacol Sci. 2021 Dec;25(23):7476-7485. doi: 10.26355/eurrev_202112_27447. Eur Rev Med Pharmacol Sci. 2021. PMID: 34919250 Free article. Clinical Trial.
They were treated for 3 months either with oral contraceptive pills (OCP) drospirenone/ethinylestradiol (group A), myo-Inositol (myo-Ins) (group B), or OCP plus myo-Ins (group C). ...
They were treated for 3 months either with oral contraceptive pills (OCP) drospirenone/ethinylestradiol (group A), myo-Inositol (myo- …
Effectiveness and safety assessment of drospirenone/ethinyl estradiol tablet in treatment of PCOS patients: a single center, prospective, observational study.
Li L, Zhang R, Zeng J, Ke H, Peng X, Huang L, Zhang H, Chen Z, Li TT, Tan Q, Yang Y, Li X, Li X. Li L, et al. BMC Womens Health. 2020 Feb 27;20(1):39. doi: 10.1186/s12905-020-00905-x. BMC Womens Health. 2020. PMID: 32106860 Free PMC article.
BACKGROUND: To investigate the effectiveness and safety of 3 mg drospirenone and 20 mug ethinyl estradiol tablet (3 mg DRSP/20 mug EE) in the treatment of polycystic ovary syndrome (PCOS). ...
BACKGROUND: To investigate the effectiveness and safety of 3 mg drospirenone and 20 mug ethinyl estradiol tablet (3 mg DRSP/20 mug EE …
The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium.
Rapkin RB, Creinin MD. Rapkin RB, et al. Expert Opin Pharmacother. 2011 Oct;12(15):2403-10. doi: 10.1517/14656566.2011.610791. Epub 2011 Aug 31. Expert Opin Pharmacother. 2011. PMID: 21877996 Review.
INTRODUCTION: Neural tube defects are the second most common congenital anomaly in the United States, although their incidence may be decreased by periconception folic acid supplementation. A new oral contraceptive containing drospirenone and ethinyl estradiol plus levomef …
INTRODUCTION: Neural tube defects are the second most common congenital anomaly in the United States, although their incidence may be decrea …
Hormonal contraception in women with endometriosis: a systematic review.
Grandi G, Barra F, Ferrero S, Sileo FG, Bertucci E, Napolitano A, Facchinetti F. Grandi G, et al. Eur J Contracept Reprod Health Care. 2019 Feb;24(1):61-70. doi: 10.1080/13625187.2018.1550576. Epub 2019 Jan 21. Eur J Contracept Reprod Health Care. 2019. PMID: 30664383
Only two COC preparations (ethinylestradiol [EE]/norethisterone acetate [NETA] and a flexible EE/drospirenone regimen) demonstrated significantly increased efficacy compared with placebo. ...
Only two COC preparations (ethinylestradiol [EE]/norethisterone acetate [NETA] and a flexible EE/drospirenone regimen) demonstrated s …
Safety and Efficacy of Combined Oral Contraceptive Ethinyl Estradiol/Drospirenone (YAZ) in Chinese Women: A Single-Arm, Open-Label, Multicenter, Post-Authorization Study.
Sun X, Qian F, He Y, Gu X, Di W. Sun X, et al. Adv Ther. 2020 Feb;37(2):906-917. doi: 10.1007/s12325-019-01210-2. Epub 2020 Jan 16. Adv Ther. 2020. PMID: 31950432
INTRODUCTION: The study was conducted to assess the safety and efficacy of a combined oral contraceptive, YAZ, containing 3 mg drospirenone/20 mug ethinyl estradiol administered in a 24/4 regimen. ...
INTRODUCTION: The study was conducted to assess the safety and efficacy of a combined oral contraceptive, YAZ, containing 3 mg drospireno …
313 results